Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Avacopan in Hepatic Impairment
NCT06004934Phase 1Completed
- Sponsor
- Amgen
- Start
- Apr 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of avacopan in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) (3 arms), sponsored by Amgen. Primary endpoints: Maximum Plasma Concentration, Time of Maximum Plasma Concentration and 4 more. Started Apr 2018; status: completed.
02
Drugs
avacopan
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06004934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06004934.